title: Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis.
abstract: BACKGROUND
  Topical nasal corticosteroids are rapidly gaining acceptance as first-line therapy for seasonal allergic rhinitis, but there is a desire for effective corticosteroids with an improved safety profile over existing products.
  
  
  OBJECTIVE
  A multicenter, double-blind dose ranging study was conducted to compare the activity and tolerance of four doses of mometasone furoate nasal spray (tradename Nasonex) and placebo in adult patients with seasonal allergic rhinitis.
  
  
  METHODS
  Four hundred eighty patients with seasonal allergic rhinitis were enrolled and randomized to receive mometasone furoate nasal spray 50 micrograms (n = 96), 100 micrograms (n = 95), 200 micrograms (n = 98) or 800 micrograms (n = 95), or placebo vehicle (n = 95) once daily for 28 days.
  
  
  RESULTS
  All of the doses of mometasone furoate nasal spray showed activity in reducing the severity of rhinitis. The 200-microgram dose reduced total nasal symptom scores and total symptom scores throughout the study (P < .05 versus placebo vehicle). The 50-microgram dose and the 100-microgram dose showed less consistent activity at early timepoints (days 3 and 7), while the 800 microgram dose did not provide significant additional benefits over the 200-microgram dose. All dose levels were well tolerated
  
  
  CONCLUSIONS
  The results of this trial indicate that 200 micrograms once daily is the optimum dose of mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis.
authors.affiliation: AAAA Medical Research Group, Salt Lake City, UT, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Bronsky
authors.forename: D W
authors.initials: DW
authors.lastname: Aaronson
authors.forename: R B
authors.initials: RB
authors.lastname: Berkowitz
authors.forename: P
authors.initials: P
authors.lastname: Chervinsky
authors.forename: D
authors.initials: D
authors.lastname: Graft
authors.forename: H B
authors.initials: HB
authors.lastname: Kaiser
authors.forename: B
authors.initials: B
authors.lastname: Moss
authors.forename: R A
authors.initials: RA
authors.lastname: Nathan
authors.forename: D S
authors.initials: DS
authors.lastname: Pearlman
authors.forename: P H
authors.initials: PH
authors.lastname: Ratner
authors.forename: J M
authors.initials: JM
authors.lastname: Adelglass
authors.forename: D L
authors.initials: DL
authors.lastname: Southern
authors.forename: J
authors.initials: J
authors.lastname: van Bavel
authors.forename: F
authors.initials: F
authors.lastname: Hampel
authors.forename: W E
authors.initials: WE
authors.lastname: Stricker
authors.forename: J A
authors.initials: JA
authors.lastname: Fourré
authors.forename: F M
authors.initials: FM
authors.lastname: Cuss
authors.forename: K B
authors.initials: KB
authors.lastname: Nolop
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate